Lost Work, ER Visits Urged in Drug Panel’s Migraine Analysis

Feb. 26, 2020, 9:04 PM

Lost work days and time spent in emergency rooms should have weighed more heavily in an analysis of migraine medicines by an influential advisory board, advocates said.

The Institute for Clinical and Economic Review, a nonprofit that analyzes whether a drug’s outcome for patients justifies its price tag, can sway insurers’ decisions on drug coverage. It recently determined that Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and rimegepant—a Biohaven drug still being considered for approval by the FDA—aren’t superior to older, cheaper drugs already on the market.

Instead, the panel recommended certain patients try those older medications before moving on to newer, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.